iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.
August 12, 2021
· 12 min read